Announcements

DuPont de Nemours, Inc. officer Lori Koch filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 2,311 shares of common stock to be acquired through a broker-assisted cashless exercise of employee stock options on the same date.

James M. Frates, an officer of Amylyx Pharmaceuticals, Inc., filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 40,000 shares of common stock to be acquired through the exercise of stock options.

Director and Officer Joshua Barry Cohen filed a Form 144 notice of proposed sale of 100,000 shares of Amylyx Pharmaceuticals Inc common stock on November 9, 2026, pursuant to Rule 144 under the Securities Act of 1933.

An amended Form 144 notice of proposed sale was filed on November 9, 2026, disclosing that First Horizon Corp officer and director Jordan D. Bryan intends to sell 100,932 shares of common stock through Fidelity Brokerage Services LLC.

Dianthus Therapeutics, Inc. officer Ryan Savitz filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 124,042 shares of common stock acquired through the exercise of stock options.

A Form 144 notice of proposed sale was filed on November 9, 2026, by the Rezk Family Trust UAD 02/15/2022, disclosing a plan to sell 50,000 shares of common stock in Aeva Technologies, Inc. on NASDAQ.

Brad C. Brubaker, an officer of UiPath, Inc., filed a Form 144 notice on November 9, 2026, proposing the sale of 27,404 shares of UiPath common stock on the NYSE under a Rule 10b5-1 plan.